Trial Profile
A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GWCO
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 23 Mar 2012 A supplemental marketing authorisation application has been submitted to the EMA for use of exenatide as add-on therapy to basal insulin and was subsequently approved by the European Commission, according to an Amylyn media release.
- 28 Jun 2011 Bodyweight outcomes presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 23 Dec 2010 Based on results from this study, a supplemental New Drug Application has been submitted to the US FDA for the expanded use of exenatide as add-on therapy to basal insulin in patients with type 2 diabetes mellitus, according to an Eli Lilly media release.